Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV for the commercialization of OMS103, Omeros' product for arthroscopic surgery.

16 Jun 2015

TSRI scientists awarded $2.1 million grant to study protein closely linked to Parkinson's disease

Scientists from the Florida campus of The Scripps Research Institute have been awarded $2.1 million from the National Institute of Neurological Disorders and Stroke of The National Institutes of Health (NIH) to study a protein that has been closely linked in animal models to Parkinson's disease and Huntington's disease.

10 Jun 2015

People with cognitive impairment have altered responses to pain

People with dementia and other forms of cognitive impairment (CI) have altered responses to pain, with many conditions associated with increased pain sensitivity, concludes a research review in PAIN, the official publication of the International Association for the Study of Pain.

29 May 2015

UC San Diego Health System designated as Center of Excellence for Huntington's disease

The Huntington's Disease Clinical Research Center at UC San Diego Health System has been designated a Center of Excellence by the Huntington's Disease Society of America. UC San Diego was one of only 29 centers nationwide to receive this prestigious designation, which recognizes centers for their elite multidisciplinary approach to Huntington's disease care and research.

27 May 2015

Omeros receives EMA CHMP positive opinion for Omidria for cataract, IOL replacement surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Omidria® (phenylephrine and ketorolac injection) 1%/0.3%.

22 May 2015

Study finds similarity in clinical progression between human patients and Huntington's disease monkeys

Transgenic Huntington's disease monkeys show similarity to humans with Huntington's in their progressive neurodegeneration and decline of motor control, scientists from Yerkes National Primate Research Center, Emory University, report.

14 May 2015

Researchers identify gene variant that affects onset of Huntington's disease

Researchers at Sweden's Karolinska Institutet and the University of British Columbia, Canada, have identified a gene variant that influences whether Huntington's disease breaks out earlier or later than expected. The findings, which are published in the scientific journal Nature Neuroscience, can contribute to improved diagnosis and disease-modifying therapies.

5 May 2015

New understanding of how Huntington's disease gene works

Huntington's disease is caused by a mutation in the Huntington's disease gene, but it has long been a mystery why some people with the exact same mutation get the disease more severely and earlier than others. A closer look at the DNA around the Huntington's disease (HD) gene offers researchers a new understanding of how the gene is controlled and how this affects the disease.

5 May 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.

30 Apr 2015

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences, Inc. announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics will be presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy

29 Apr 2015

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit.

29 Apr 2015

Study could lead to new therapeutic targets for treating Huntington's disease

An international study led by researchers from Université Laval and CHU de Québec-Université Laval has identified significant vascular changes in the brains of people with Huntington's disease. This breakthrough, the details of which are published in the most recent issue of Annals of Neurology, will have significant implications for our understanding of the disease and could open the door to new therapeutic targets for treating this fatal neurodegenerative condition.

17 Apr 2015

Plymouth researchers receive grant to develop effective therapy for Huntington's disease

Huntington's disease is an hereditary disorder of the nervous system caused by a faulty gene on chromosome four. The faulty gene leads to nerve damage in the area of the brain resulting in gradual physical, mental and emotional changes. Those born to a parent with Huntington's disease have a 50:50 chance of developing it, and there is currently no cure.

9 Apr 2015

Study: Broken communication in brain regions appears to worsen Huntington's disease

Indiana University researchers have found that broken communication in a specific part of the brain plays a role in the involuntary physical movements that affect individuals with Huntington's disease.

7 Apr 2015

Omeros announces commercial availability of Omidria in U.S.

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, announced today the nationwide commercial availability of Omidria (phenylephrine and ketorolac injection) 1%/0.3%.

2 Apr 2015

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences, Inc. today announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma Corporation.

1 Apr 2015

Northwestern Medicine opens multidisciplinary treatment center for patients battling Huntington's disease

Northwestern Medicine recently launched a multidisciplinary center dedicated to the comprehensive treatment of patients battling Huntington's disease. The new center will focus on both patient care and research of the inherited disease that causes the progressive breakdown of nerve cells in the brain.

31 Mar 2015

Broad Institute of MIT researcher honored for groundbreaking research using new gene editing tool

The newest gene editing tool - called CRISPR-Cas9 - is leading to new research possibilities in cell biology and neuroscience. This includes the ability to make transgenic animal models more quickly, which helps researchers better study diseases that affect thousands of people each year.

25 Mar 2015

IUPUI professor receives grant to model human motor movements for Huntington's research

Yaroslav Molkov, assistant professor of mathematics in the School of Science at Indiana University-Purdue University Indianapolis, in collaboration with researchers at Drexel University College of Medicine, Philadelphia, has received a grant to use computational modeling to map a motor control system to study Huntington's disease.

20 Mar 2015

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit.

11 Mar 2015

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

TSRI scientists awarded $2.1 million grant to study protein closely linked to Parkinson's disease

People with cognitive impairment have altered responses to pain

UC San Diego Health System designated as Center of Excellence for Huntington's disease

Omeros receives EMA CHMP positive opinion for Omidria for cataract, IOL replacement surgery

Study finds similarity in clinical progression between human patients and Huntington's disease monkeys

Researchers identify gene variant that affects onset of Huntington's disease

New understanding of how Huntington's disease gene works

Neurocrine reports net loss of $1.2 million for first quarter 2015

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Study could lead to new therapeutic targets for treating Huntington's disease

Plymouth researchers receive grant to develop effective therapy for Huntington's disease

Study: Broken communication in brain regions appears to worsen Huntington's disease

Omeros announces commercial availability of Omidria in U.S.

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Northwestern Medicine opens multidisciplinary treatment center for patients battling Huntington's disease

Broad Institute of MIT researcher honored for groundbreaking research using new gene editing tool

IUPUI professor receives grant to model human motor movements for Huntington's research

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in